Vifor Pharma Ag Stock Earnings Per Share
| GNHAYDelisted Stock | USD 38.39 0.00 0.00% |
Vifor Pharma AG fundamentals help investors to digest information that contributes to Vifor Pharma's financial success or failures. It also enables traders to predict the movement of Vifor Pink Sheet. The fundamental analysis module provides a way to measure Vifor Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vifor Pharma pink sheet.
Vifor |
Vifor Pharma AG Company Earnings Per Share Analysis
Vifor Pharma's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Vifor Pharma Earnings Per Share | 0.49 X |
Most of Vifor Pharma's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vifor Pharma AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, Vifor Pharma AG has an Earnings Per Share of 0.49 times. This is 94.15% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The earnings per share for all United States stocks is 84.29% higher than that of the company.
Vifor Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vifor Pharma's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Vifor Pharma could also be used in its relative valuation, which is a method of valuing Vifor Pharma by comparing valuation metrics of similar companies.Vifor Pharma is currently under evaluation in earnings per share category among its peers.
Vifor Fundamentals
| Return On Equity | 0.0665 | |||
| Return On Asset | 0.0458 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.21 % | |||
| Current Valuation | 10.99 B | |||
| Shares Outstanding | 324.46 M | |||
| Price To Earning | 30.39 X | |||
| Price To Book | 3.22 X | |||
| Price To Sales | 6.39 X | |||
| Revenue | 1.82 B | |||
| Gross Profit | 1.14 B | |||
| EBITDA | 519.6 M | |||
| Net Income | 144.4 M | |||
| Cash And Equivalents | 993.6 M | |||
| Cash Per Share | 3.06 X | |||
| Total Debt | 75 M | |||
| Debt To Equity | 0.15 % | |||
| Current Ratio | 1.91 X | |||
| Book Value Per Share | 10.76 X | |||
| Cash Flow From Operations | 527.4 M | |||
| Earnings Per Share | 0.49 X | |||
| Number Of Employees | 2.2 K | |||
| Beta | 1.03 | |||
| Market Capitalization | 12.45 B | |||
| Total Asset | 5.1 B | |||
| Retained Earnings | 2.01 B | |||
| Working Capital | 567 M | |||
| Current Asset | 1.29 B | |||
| Current Liabilities | 726 M | |||
| Z Score | 99.6 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 5.1 B | |||
| Last Dividend Paid | 2.0 |
About Vifor Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vifor Pharma AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vifor Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vifor Pharma AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Vifor Pink Sheet
If you are still planning to invest in Vifor Pharma AG check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vifor Pharma's history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |